ticlopidiini

Ticlopidine is an antiplatelet medication used to prevent blood clots in certain medical conditions. It belongs to a class of drugs called thienopyridines and works by irreversibly inhibiting the P2Y12 adenosine diphosphate (ADP) receptor on the surface of platelets. This inhibition prevents ADP from binding to the receptor, which in turn reduces platelet activation and aggregation.

The primary indication for ticlopidine has been the prevention of thrombotic events, such as stroke or transient ischemic attack (TIA), in patients who cannot tolerate aspirin or have experienced a TIA or stroke. It has also been used in patients with peripheral arterial disease and in those undergoing certain cardiovascular procedures.

Ticlopidine is administered orally. Its effects on platelet aggregation are irreversible and last for the lifespan of the platelet, which is about 7 to 10 days. Therefore, its antiplatelet effect persists for several days after discontinuation of the drug.

While effective, ticlopidine has a significant side effect profile, which has led to its replacement by newer and safer antiplatelet agents in many clinical settings. Notable adverse effects include neutropenia (a decrease in white blood cells), thrombocytopenia (a decrease in platelets), and gastrointestinal disturbances. Severe hematological reactions, though rare, can be life-threatening. Because of these risks, ticlopidine is typically reserved for situations where other antiplatelet therapies are contraindicated or have failed.